Le Lézard3d
Response Pharmaceuticals Announces Early Completion of Enrollment of a Phase 2 Study Evaluating RDX-002 Treating Patients Discontinuing GLP-1 Agonists
Response Pharmaceuticals, Inc., a clinical-stage company focused on weight management and metabolic health in high-risk populations, today announced the early completion of enrollment in a Phase 2 ...
Le Lézard3d
Genomenon and Mirum Pharmaceuticals Join Forces to Enhance CTX Disease Awareness and Diagnosis
Genomenon, Inc., a leading provider of genomic intelligence solutions, has announced a strategic partnership with Mirum Pharmaceuticals, Inc. to improve the awareness and diagnosis of Cerebrotendinous ...
NurExone Forms Exo-Top Inc. in the U.S. for Exosome Manufacture and Commercialization
Detailed price information for Nurexone Biologic Inc (NRX-X) from The Globe and Mail including charting and trades.
HOPE Therapeuticstm, Inc. And Nrx Pharmaceuticals, Inc. (NASDAQ:NRXP) Engage BTIG As Financial Advisor
The Company has recently announced execution of an agreement for $27 million in funding for HOPE Clinic Acquisition. Upon closing of the first tranch ...
NRx Pharmaceuticals, Hope Therapeutics engage BTIG as financial advisor
Hope Therapeutics, a wholly-owned subsidiary of NRx Pharmaceuticals (NRXP), announced engagement of BTIG, a leading global financial services ...
HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Engage BTIG as Financial Advisor
HOPE Therapeutics™, Inc. ("HOPE"), a medical and technology driven company, and a wholly-owned subsidiary of NRx ...